New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2014
09:36 EDTLNKD, TSLA, GILD, AAPL, CActive equity options trading
Active equity options trading on open according to Track Data: AAPL TSLA C X GILD LNKD KO MSFT
News For AAPL;TSLA;C;GILD;LNKD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>
July 16, 2015
07:19 EDTAAPLApple Q3 iPhone estimates raised at Stifel
Subscribe for More Information
06:58 EDTAAPLApple applies for patent for wireless devices with solar cells
Subscribe for More Information
06:46 EDTAAPLApple Watch to roll out in New Zealand July 31, AppleInsider reports
Subscribe for More Information
July 15, 2015
16:00 EDTC, AAPLOptions Update; July 15, 2015
Subscribe for More Information
15:27 EDTCCiti July 56.5 straddle priced for 2.4% movement into Q2
14:53 EDTCNotable companies reporting before tomorrow's open
Subscribe for More Information
14:26 EDTLNKDLinkedIn heads higher after Barclays ups rating ahead of earnings
Subscribe for More Information
14:05 EDTCCiti reports June credit loss 2.49% vs. 2.86% last month
Subscribe for More Information
13:56 EDTCEarnings Watch: Analysts mixed on Citi after settlements, asset sales
Subscribe for More Information
13:50 EDTCEarnings Watch: Goldman Sachs to report after last quarter's earnings beat
Subscribe for More Information
12:38 EDTAAPLGundlach says out of Apple position
Subscribe for More Information
11:01 EDTAAPLApple introduces new iPod touch, unveils new colors for iPod models
Subscribe for More Information
10:01 EDTLNKDOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AGCO (AGCO) upgraded to Market Perform from Underperform at Wells Fargo... Anglo American (AAUKY) upgraded to Outperform from Neutral at Credit Suisse... Avis Budget (CAR) upgraded to Buy from Hold at Deutsche Bank... Brookfield Renewable (BEP) upgraded to Neutral from Underperform at Credit Suisse... CSX (CSX) upgraded to Outperform from Sector Perform at RBC Capital... Centene (CNC) upgraded to Buy from Hold at Jefferies... Commerce Bancshares (CBSH) upgraded to Market Perform at Raymond James... Entegris (ENTG) upgraded to Buy at Craig-Hallum... Guess (GES) upgraded to Market Perform from Underperform at Telsey Advisory... Hertz (HTZ) upgraded to Buy from Hold at Deutsche Bank... Iberdrola (IBDRY) upgraded to Buy from Hold at Societe Generale... Liberty Global (LBTYA) upgraded to Conviction Buy from Buy at Goldman... LinkedIn (LNKD) upgraded to Overweight from Equal Weight at Barclays... Lonmin (LNMIY) upgraded to Neutral from Sell at Goldman... Navient (NAVI) upgraded to Overweight from Equal Weight at Barclays... NetApp (NTAP) upgraded to Sector Weight from Underweight at Pacific Crest... Omnicom (OMC) upgraded to Outperform from Market Perform at Wells Fargo... PTC Therapeutics (PTCT) upgraded to Overweight from Neutral at JPMorgan... Panera Bread (PNRA) upgraded to Overweight from Underweight at Piper Jaffray... Primerica (PRI) upgraded to Strong Buy from Market Perform at Raymond James... Sands China (SCHYY) upgraded to Overweight from Equal Weight at Barclays... Seagate (STX) upgraded to Buy at Craig-Hallum... Western Digital (WDC) upgraded to Buy from Hold at Craig-Hallum... Wolseley (WOSYY) upgraded to Overweight from Neutral at JPMorgan.
09:53 EDTAAPLHSBC UK says Apple Pay support coming within 2 weeks, Apple Insider says
HSBC UK (HSBC) said that Apple Pay (AAPL) support is in its final testing and availability will be coming within two weeks, reports Apple Insider. An HSBC spokesperson said, "We are excited to be one of a small number of Apple Pay launch partners. We have been working closely with Apple and are now properly reviewing and testing our systems before launching in two weeks." Reference Link
09:32 EDTAAPLActive equity options trading on open
Active equity options trading on open: AAPL FB BAC RCPT MU YUM NFLX CELG
07:58 EDTGILDAnalysts break down impact of $7.2B Receptos buyout
After Celgene (CELG) announced last night that the company has agreed to acquire Receptos (RCPT) for $232 per share in cash, or a total of about $7.2B net of cash acquired, research firms have chimed in with their opinions on how the proposed deal may impact others in the biotech space. Receptos key asset is Ozanimod, which is being studied in Phase III trials for relapsing multiple sclerosis and ulcerative colitis. DERIVATIVE CALLS: Piper Jaffray analyst Edward Tenthoff told investors that he views Celgene's deal for Receptos as good for Arena Pharmaceuticals (ARNA). The analyst notes that Arena's APD334 is already showing dose-dependent decreases in circulating lymphocyte counts and that the company will initiate Phase II studies in ulcerative colitis and Crohn's disease this year. Tenthoff reiterates an Overweight rating and $7.50 price target on Arena, which has a market capitalization around $1B and closed yesterday up 8c to $4.47. In its own note to investors this morning, Nomura said Celgene's deal could put downward pressure on Biogen's (BIIB) long-term multiple sclerosis estimates. Nomura's M. Ian Somaiya contended that one-year Phase II efficacy data for Ozanimod looked as good as Novartis’s (NVS) Gilenya and Biogen's Tecfidera’s Phase III at year 2. Somaiya also wondered if rival Gilead (GILD) could be "looking for something bigger" than Receptos for its own deal, telling investors that the firm views Incyte (INCY) as Gilead's most likely takeout target. Incyte's shares closed up $4.46 at $117.46 yesterday, giving the company a market cap of about $20B. RIVAL BID?: Wedbush analyst Liana Moussatos believes another bidder may seek to acquire Receptos, noting that she previously estimated Receptos could be valued at $348 per share, or about $10.9B, in a buyout. Moussatos noted that Celgene said it expects annual peak sales for Ozanimod to reach about $4B-$6B for RMS and UC, making its acquisition price of $7.2BN only a bit more than about 1X peak sales without accounting for other possible indications or the rest of its pipeline. Moussatos told investors she sees "plenty" of potential upside to justify a rival bidder stepping in and reiterated the firm's Outperform rating on Receptos shares. PRICE ACTION: In pre-market trading, Receptos rose 10% to $228.61 while Gilead gained 1.4% to about $119 per share.
06:39 EDTAAPLApple to release new iPod touch, 9to5Mac reports
Subscribe for More Information
06:33 EDTAAPLApple 'in touch' with Iranian distributors to sell products there, WSJ reports
Subscribe for More Information
06:32 EDTTSLATesla buys 2,000 extra acres for Nevada factory, WSJ reports
Tesla has almost tripled its land holdings in Nevada recently, having bought nearly 2,000 additional acres near Reno as it works on a factory intended to build batteries for electric cars and stationary backup batteries, the Wall Street Journal reports. Tesla originally bought 1,000 acres last year, though that agreement including options to purchase additional land, the report says. Reference Link
05:44 EDTLNKDLinkedIn upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Paul Vogel upgraded LinkedIn to Overweight and raised his price target for shares to $250 from $225. Shares of the professional social network closed yesterday up 60c to $213.93. Expectations have been reset following LinkedIn's weaker than expected Q1 results, and estimates for the back half of 2015 have potential upside, Vogel tells investors this morning in a research note. The analyst views the Lynda acquisition guidance as conservative and is more positive on the company's Sales Navigator opportunity following his survey work. He views the issues hurting LinkedIn's Q1 results as transitory in nature and recommends buying the stock into the back half of the year.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use